Marco Boorsma PhD
General Partner
Developing disease-modifying precision therapeutics for patients with serious genetic diseases
Rectify is developing Positive Functional Modulators (PFMs), disease-modifying precision therapeutics that restore ABC transporter function for patients with serious genetic diseases.
ABC transporters are a 48-member family of membrane-bound proteins with etiologic loss-of-function mutations in multiple organ systems and therapeutic areas including the lungs, liver, gastrointestinal tract, eye, and central nervous system.
Industry
Biotech
Status
Current
Location
US
Our partnership with Forbion has been instrumental to Rectify's progress and success. Forbion has provided not just capital, but deep strategic insight based on an appreciation and understanding of novel, oral small molecule drug development. As we advance from discovery towards the clinic, we look forward to our continued work with Forbion to deliver transformative, disease-modifying positive functional modulators that bring hope to patients living with serious diseases.Rajesh Devraj
CEO of Rectify Pharma
$100M
Series A financing
Forbion team